You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK):多索茶鹼注射液及鹽酸氨溴索注射液在全國藥品集中採購招標中中標
格隆匯 02-03 18:11

格隆匯 2 月 3日丨石四藥集團(02005.HK)發佈公吿,集團產品聚丙烯安瓿包裝的多索茶鹼注射液及鹽酸氨溴索注射液於2021年2月3日的中國全國藥品集中採購招標中中標。集團的多索茶鹼注射液及鹽酸氨溴索注射液分別於2020年1月及2020年12月通過仿製藥質量和療效一致性評價。

根據全國藥品集中採購招標安排,集團多索茶鹼注射液將獨家供應湖北、雲南、重慶、黑龍江、內蒙古和寧夏共6個省市,而鹽酸氨溴索注射液將獨家供應上海、天津及青海共3個省市。董事局預期是次中標將有利相關新產品迅速開發市場,形成規模銷售,提高市場佔有率,對集團未來銷售帶來正面的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account